Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of AZD0284 in Healthy Subjects
NCT03029741Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD0284 in plaque psoriasis, sponsored by AstraZeneca. Primary endpoints: Absolute Bioavailability of AZD0284 at 72 hours, Maximum Plasma Concentration (Cmax) at 72 hours and 3 more. Started Feb 2017; status: completed.
02
Drugs
AZD0284
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03029741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029741.